On April 14, 2022, Evelo Biosciences, Inc. announced that it plans to meet with health authorities to discuss the path forward to registration trials for EDP1815 in patients with psoriasis during the third quarter of 2022. EDP1815 - Atopic Dermatitis: On April 14, 2022, the Company announced that, subject to regulatory approval, it intends to add a cohort to its on-going Phase 2 trial of EDP1815 in mild, moderate, and severe atopic dermatitis. Patients in this cohort, if approved, will receive one capsule of EDP1815 with a faster release profile once daily.

The Company also announced that on-going recruitment for the Phase 2 atopic dermatitis trial is ahead of plan. The Company expects that data from the first 3 cohorts of the Phase 2 atopic dermatitis trial will be available in the first quarter of 2023 and that data from the additional fourth cohort, if approved, will be available in the first half of 2023. EDP1867 - Atopic Dermatitis: On April 14, 2022, the Company announced that data from a Phase 1b clinical trial of EDP1867 in patients with atopic dermatitis (n=52, with 40 participants who had at least one dose of EDP1867) suggested EDP1867 was safe and well-tolerated in both healthy volunteers and patients with moderate atopic dermatitis across all doses tested.

No clear evidence of clinical benefit was observed in the small set of patients (n=15) with atopic dermatitis who received the lower dose of EDP1867 and provided analyzable data at week 8. Additionally, the Company announced that it intends to put the EDP1867 program on hold to focus efforts on its lead inflammation programs EDP1815 and EDP2939.